TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02054377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai chi
Description: Tai Chi, a Chinese form of mindful exercise, may help alleviate CF symptoms, encourage active self-management and provide a practical way to relieve and manage stress for patients and carers. It involves gentle physical exercises, combined with breathing techniques and mindful awareness.~It will be taught by qualified instructors either face to face in the participant's home or over videoconferencing technology e.g. Skype.~A DVD of the Tai Chi was developed in Phase 1 which was successful for teaching adults, and will be used here, along with a child-friendly DVD. This will be filmed with and aimed at children aged 6-18. Teaching support materials, incorporating child-specific guidance such as animal-based Tai Chi movements, will be prepared for use in conjunction with the DVD.
Study: NCT00398879

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Perifosine Placebo
Description: Placebo to Perifosine 50 mg/d qd
Study: NCT04317976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: paralaryngeal pressure
Description: cricoid pressure with paralaryngeal pressure by fingertips applied under ultrasound guidance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cricoid pressure
Description: cricoid pressure by fingertips applied under ultrasound guidance
Study: NCT02055807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP and recruitment maneuvers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ZEEP (no PEEP nor recruitment maneuver)
Study: NCT03796533

Intervention type: DRUG
Group type: OTHER
Intervention: Posaconazole
Description: * PCZ will be used as recommended in tablet formulation at an initial dosage of 300 mg twice a day on the first day and then once a day at a dose of 300 mg the following days.~* PCZ prophylaxis will be started on the same day as the start of chemotherapy and will be continued until the end of aplasia.~* The dosage of the PCZ can be adjusted according to the results of the PCZ assay. It may be interrupted if the transaminase level is greater than 3 times higher than normal (3N) or on medical decision.
Study: NCT03773380

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Breathe Anew Survivorship Program
Description: The feasibility will be tested of the Breathe Anew Survivorship Program
Study: NCT00950495

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Advancement Device (MAD)
Description: This oral appliance keeps the mandible and the tongue in a protruded position. This results in an upper respiratory tract widening and/or reduced collapsibility of the upper airway, thereby preventing the upper airway collapse during sleep.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal CPAP
Description: The CPAP machine delivers a stream of compressed air via a hose to a nose mask, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible, reducing and/or preventing apneas and hypopneas

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: as a placebo, a thin (\< 1 mm), hard acrylic-resin palatal splint with only a partial palatal coverage was used
Study: NCT04840732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR training program
Description: Use VR software to make a training education program.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: Chemotherapy training as usual care (for training chemotherapy skill).
Study: NCT00833716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 10 mg/mL of semaglutide solution for s.c. injection, single dose
Study: NCT01674283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00244517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl
Description: TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV
Study: NCT03982173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: tremelimumab 75mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg
Study: NCT03411187

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: used of the Pressure adjustable foot-control method
Description: Whether The Pressure adjustable foot-control method is used.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: direct exhaust
Description: direct exhaust through the trocar.
Study: NCT04250207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-321 Solution
Description: K-321 solution drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-321 Solution
Description: K-321 solution drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Solution
Description: Placebo solution drops for K-321
Study: NCT04417062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib is taken by mouth, twice daily on days 1-14 of the study cycle.
Study: NCT00244517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl
Description: TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl
Description: TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane, Isoflurane, Desflurane
Description: 1 MAC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane, Isoflurane, Desflurane
Description: 1 MAC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane, Isoflurane, Desflurane
Description: 1 MAC
Study: NCT01133041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation using NBI system
Description: NBI system can improve the patterns of mucosal surface and vascularity of colonic polyp.
Study: NCT01953172

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04157972

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIMEOX
Description: SIMEOX is a device generating a succession of gentle depression at the mouth.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEP
Description: A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
Study: NCT01133041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation using i-Scan system
Description: I-Scan system can improve the patterns of mucosal surface and vascularity of colonic polyp.
Study: NCT02952729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XMT-1522
Description: one intravenous dose administered in-clinic every 21 days
Study: NCT03874026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfiri/Cetuximab
Description: Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered.
Study: NCT01731236

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carnitine
Description: Group 1: Carnitine supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Choline
Description: Group 2: Choline supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Group 3: Carnitine or Choline for 2 months, antibiotic cocktail (Ciprofloxacin, Flagyl, Vancomycin, and Neomycin) for 1 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choline and Aspirin
Description: Group 4: Choline supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carnitine and Aspirin
Description: Group 5: Carnitine supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
Study: NCT02112929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized xenon
Description: Inhalation of up to one litre of polarized xenon gas, up to four inhalations per day are permitted.
Study: NCT01147770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progesterone
Description: duration
Study: NCT00441675

Intervention type: PROCEDURE
Intervention: Symptom Score
Description: Symptom Score

Intervention type: PROCEDURE
Intervention: Symptom Score
Description: Symptom Score

Intervention type: PROCEDURE
Intervention: Symptom Score and PD20
Description: Symptom Score and PD20

Intervention type: PROCEDURE
Intervention: Symptom Score and PD20
Description: Symptom Score and PD20
Study: NCT01077245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIYA-BM Fine Granules (CBM588)
Description: MIYA-BM Fine Granules (CBM588)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Fine Granules (without CBM588)
Description: Placebo Fine Granules (without CBM588)
Study: NCT00875628

Intervention type: DRUG
Group type: OTHER
Intervention: PF-00868554 or Placebo
Description: Dosage Form: Oral solution Dosage: PF-00868554 100 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: PF-00868554 or Placebo
Description: Dosage Form: Oral solution Dosage: PF-00868554 300 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: PF-00868554 or Placebo
Description: Dosage Form: Tablet Dosage: PF-00868554 600 mg or placebo under fed conditions Frequency: BID (twice daily) Duration: 14 days
Study: NCT02138916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab Arm A
Description: Benralizumab subcutaneously on study week 0 until study week 48 inclusive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab Arm B
Description: Benralizumab subcutaneously on study week 0 until study week 48 inclusive

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously on study week 0 until study week 48 inclusive
Study: NCT04746820

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: single-center prospective pilot study
Description: fNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects.~To compare fNIRS with evoked potentials there are two test phases:~1. The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP~2. The cerebral response to an auditory stimulus is measured by fNIRS and AEP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single-center prospective pilot study
Description: fNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects.~To compare fNIRS with evoked potentials there are two test phases:~1. The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP~2. The cerebral response to an auditory stimulus is measured by fNIRS and AEP
Study: NCT02391662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4
Description: Nab-paclitaxel 125 mg/m2 days 1,8 \& 15 in a 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 weeks 1,2,3/4
Description: Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
Study: NCT04382677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships ®
Description: Promoting First Relationships ® is based on attachment theory and is strengths-based. The 12 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting.

Intervention type: OTHER
Group type: OTHER
Intervention: Resource & Referral
Description: This condition consists of 1) Resource \& Referral assistance provided over the phone, and 2) Local Services Resource Packet. Throughout the intervention period, the provider makes monthly phone calls to offer further support to families, answer questions, and provide additional resources. The provider has at least four interactions with each family served. In addition, families in this condition have the Resource and Referral Specialist's phone number and they can call if an additional need arises. The resource packet includes local information organized by type of need or resource. These packets are updated regularly as services change over time.
Study: NCT00754988

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: As prescribed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As prescribed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matching sitagliptin)
Description: Once daily oral administration of placebo (matching sitagliptin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matching sitagliptin)
Description: Once daily oral administration of placebo (matching sitagliptin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matching sitagliptin)
Description: Once daily oral administration of placebo (matching sitagliptin).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matching taspoglutide)
Description: Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (matching taspoglutide)
Description: Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Once daily oral administration of 100 mg of sitagliptin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taspoglutide
Description: Once weekly subcutaneous (sc) injection of 10 mg or 20 mg of taspoglutide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taspoglutide
Description: Once weekly subcutaneous (sc) injection of 10 mg or 20 mg of taspoglutide.
Study: NCT04562610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Infusion group
Description: The intravenous infusion group will receive two medications via the intravenous infusion route. These medications are Ofirmev ( acetaminophen ) 1,000mg and tranexamic acid 2,000 mg , an antifibrinolytic drug. In addition to these drugs, study subjects will receive Celecoxib 200mg by mouth and Gabapentin 600 mg by mouth prior to operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: All oral administration group
Description: Subjects in the oral administration group will receive the following pre-emptive analgesic drugs, acetaminophen 1,000mg, Celecoxib 200mg and gabapentin 600mg via the oral route prior to operation. In addition they will receive the antifibrinolytic drug, tranexamic acid 2,000mg via an oral route as well prior to operation.
Study: NCT02520661

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care Transitions Intervention
Description: The Care Transitions Intervention uses coaches, in this case paramedics, to support patients being discharged home by transferring skills to activate patients.
Study: NCT01863238

Intervention type: OTHER
Intervention: Ophthalmologic examinations
Description: Subjects will undergo an ophthalmologic examination at study entry (Day 1) and every 6 months thereafter for 2 years (Months 6, 12, 18, and 24). Subjects who discontinue treatment with commercially-available ivacaftor for any reason and are willing to continue participation in the study will complete the study.

Intervention type: DRUG
Intervention: Ivacaftor Exposed
Study: NCT04197752

Intervention type: OTHER
Intervention: Regional anesthesia/analgesia techniques
Description: Neuroaxial or peripheral block anesthesia/analgesia technique that is appropriate for the patient's surgery

Intervention type: OTHER
Intervention: Regional anesthesia/analgesia techniques
Description: Neuroaxial or peripheral block anesthesia/analgesia technique that is appropriate for the patient's surgery
Study: NCT03344354

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biogel
Description: Sterile surgical gloves used during surgical procedures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ansell
Description: Sterile surgical gloves used during surgical procedures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardinal
Description: Sterile surgical gloves used during surgical procedures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medline
Description: Sterile surgical gloves used during surgical procedures.
Study: NCT02035501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Tyrosine
Study: NCT03848481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBDV Compound
Description: CBDV is obtained from the Cannabis sativa L. plant and contains a negligible quantity (less than 0.2%) of THC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution contains matching excipients.
Study: NCT01420367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole and cephalzolin
Description: IV doses of metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g). One dose for study arm, two for comparative arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole and cephalzolin
Description: IV doses of metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g). One dose for study arm, two for comparative arm.
Study: NCT02035501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00200096

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture and questionnaires
Description: Acupuncture once weekly for six weeks Brief Fatigue Inventory, Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Treatment scale. Patients will repeat the BFI and FACT-G at seven and eight weeks after randomization, approximately one and two weeks after their final treatment. HADS will be repeated at week seven. At the end of the study, patients will be asked to state whether they were thought they on true or placebo acupuncture and why.~On the day of the final session of acupuncture treatment (approximately day 35), blood samples will be collected and tested for hemoglobin, thyroid function tests, as described in pretreatment evaluation. The results will be designated posttreatment values. Actigraphic monitoring will be conducted in week seven. Patients will be asked to wear the device for seven days just like during baseline evaluation.
Study: NCT00444574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Transdermal System
Description: The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concerta
Description: The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
Study: NCT02125513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin and paclitaxel followed by surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin and paclitaxel followed by surgery
Study: NCT03297983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7583
Description: Subject will receive either M7583 PiC or M7583 tablet formulation orally under fasted conditions in part 1 followed by M7583 tablet formulation under fed condition in part 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7583
Description: Subject will receive either M7583 PiC or M7583 tablet formulation orally under fasted conditions in part 1 followed by M7583 tablet formulation under fed condition in part 2 of the study.